Novartis Ends Mid-Stage Fabhalta Study in Lupus Nephritis
Novartis terminated a mid-stage clinical trial of Fabhalta in patients with lupus nephritis. The supplied report provides no reason for the termination.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Novartis ends mid — stage Fabhalta trial targeting serious kidney condition
Oct 16 (Reuters) — Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing "strategic considerations", according to a federal clinical trials registry. The trial was evaluating whether the oral medication was safe and effective for treating